Confirmed Sponsors
Diamond
Platinum
Gold
Silver
Bronze
Confirmed Sponsors
iNovation – ESCRS 2022
The European Society of Cataract and Refractive Surgeons
Confirmed Sponsors
STAAR Surgical designs, develops, manufactures, markets and implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. More than 2 million lenses have been distributed worldwide.
Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With our 70-plus-year heritage, we are the largest eye care device company in the world – with complementary businesses in Surgical and Vision Care. Being a truly global company, we work in over 70 countries and serve patients in more than 140 countries. We have a long history of industry firsts, and each year we commit a substantial amount in Research and Development to meet customer needs and patient demands.
Johnson & Johnson Vision (JJV) is a subsidiary of Johnson & Johnson and is composed of two divisions, Johnson & Johnson Surgical Vision and Johnson & Johnson Vision Care (Contact Lens).
[1] Services include Intraocular lenses, laser vision correction systems, phacoemulsification systems, viscoelastic, Microkeratomes and related products used in cataract and refractive surgery.
Johnson and Johnson Surgical Vision is based in Santa Ana, California, and Johnson & Johnson Vision Care is based in Jacksonville, Florida. JJV employs approximately 4,200 worldwide. The company has operations in 24 countries and markets products in approximately 60 countries.
In February 2017, Abbott Medical Optics changed its name to Johnson & Johnson Vision following its $4.3 billion acquisition by Johnson & Johnson.
BVI is a medical company manufacturing and distributing surgical devices dedicated to ophthalmology in more than 90 countries. BVI manufactures and distributes products to treat patients affected by eye conditions such as cataract, refractive error, glaucoma, retinal disease, and dry eye.
Unburdened by legacy or bureaucracy, we have developed our strategy around a simple concept – taking pride in delivering innovative solutions for our physicians and patients, based on their needs.
Valuing agility, simplicity, and transparency, we stay committed to listening to our customers, delivering for our patients, and keeping the future in focus.
| VSY Biotechnology is a progressive and innovative company that focuses on consumer satisfaction by creating superior state-of-the-art ophthalmology and orthopedics products designed and manufactured to greatly enhance and improve vision and comfort for a wide range of patients around the globe.
Product portfolio includes intraocular lenses to treat cataract and refractive errors like presbyopia, astigmatism and ocular problems, as well as injector and cartridge systems , viscoelastics for ophthalmology and orthopedics and hyaluronic acid (HA) viscosupplement products for orthopedics. Starting from foundation to today, quality and safety standards are the source of our success. We are serving over 80 countries around the globe from our headquarters with a professional marketing and distribution approach. With our know-how in biotechnology, we will continue to enlighten the world by combining these disciplines for the patients. The company is owned by Evmann Investments Holding BV at 100%. Evmann Investments Holding BV is a Dutch resident Holding company which currently has investments in ophthalmology and orthopedics industries. Its strategy is to make investments especially in areas creating value for a healthier life under its motto of “Invest for Life”.
|
Driving progress, efficiency and healthcare access. With a special focus on ophthalmology, ophthalmic surgery and visualization systems in the field of microsurgery, ZEISS Medical Technology supports healthcare professionals in setting new standards of care with proven medical technology and broad application competence based on cutting-edge innovations.
With nearly 170 years of innovation, Bausch+Lomb is a leading global eye care brand with expertise in contact lenses and lens care, pharmaceuticals and eye surgery. The Surgical Division provides a complete range for cataract, refractive, corneal, retinal, and glaucoma surgery.
Our comprehensive portfolio features the premium LuxSmart™ IOL, the combined Stellaris Elite™ vision enhancement system, our refractive suite with the TECHNOLAS® TENEO™ 317 Model 2 and the ACE™ Corneal Explorer, along our extensive instrument range. Bausch+ Lomb caters for individual surgeon techniques and patient needs.
DORC enhances global eye surgery and maximises surgeon control by offering innovative quality approaches for eye disorders.
Our product portfolio includes EVA NEXUS™ phaco-vitrectomy system featuring unique VTi pump offering both FLOW and VACUUM fluidics, SMART IOP™ providing more stable, lower anterior chamber pressure and constant stability, EVA EQUIPHACO™ needles designed for superior anterior chamber stability, improved ultrasound efficiency and reduced effective phaco time and VisionBlue® – the only trypan blue stain for anterior use approved by the FDA.
Inspired by you – created by DORC.
iSTAR Medical pioneers minimally invasive, ophthalmic implants for safe, meaningful and sustained treatment of glaucoma patients. MINIject® is the only commercially available supraciliary MIGS device and is made from STAR® material, which is soft and flexible, medical-grade, micro-porous silicone enabling bio-integration of surrounding tissues. Clinical trials show that IOP is reduced by 39% to a mean of 14.4mmHg at two years post-surgery. MINIject received CE marking in late 2021 and the US FDA trial (STAR-V) for MINIject is in progress.
AcuFocus, Inc., is a privately held ophthalmic medical device company that delivers breakthrough small-aperture intraocular products to address diverse unmet needs in eye care and help patients achieve their best personal vision. The IC-8™ IOL (known as the IC-8 Apthera™ IOL in the United States) uses small aperture technology to filter out peripheral defocused light, allowing only focused light to reach the retina. This provides a true continuous depth of focus.
The IC-8 Apthera IOL was FDA approved in July 2022 and is now available in the United States. The lens received CE mark in 2015 and is available in select markets across Europe as well as Australia, New Zealand, and Singapore. AcuFocus is based in Irvine, California.
For more information about AcuFocus, visit www.acufocus.com. Or The IC-8 IOL is available in the United States, Australia, New Zealand, Singapore, and select markets across Europe.
A new name in the ophthalmic industry, yet a team that embodies ophthalmology in Europe, we are Medevise Consulting. It starts with a Board of Directors led by Kristine Morrill and Paul Bikard and extends through to the management team and service leaders. Medevise Consulting represents a new approach that marries passion, experience and diligence to every project.
Our Vision: To be the partner of choice for medical device innovators in ophthalmology.
Our Mission: To put the best medical device innovation into the hands of ophthalmologists across Europe to improve patient experience and outcomes.
Our Values: We believe in working together with our clients to achieve excellence. We strive for impeccable execution – taking pride in our quality management approach. We apply creative thinking to everything to ensure we develop unique and effective solutions to all client challenges, large or small. We build client relationships for the long-haul.
OERTLI – MAKING THE DIFFERENCE IN EYE SURGERY.
Oertli develops, manufactures and distributes surgical platforms, instruments and consumables with which surgeons and OR personnel can work easier, safer and more efficient and thus achieving better results for the patient. Our ongoing innovations and new technologies have had a long-term impact on cataract, glaucoma and vitreoretinal surgeries since 1955.
The prevention of medical waste in the operating theater is a topic we take very seriously. We want to take a leading role in the sustainability of medical products in eye surgery.